ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1884

Sensitivity to Change of Nailfold Videocapillaroscopy and Relationship with Disease Progression

Jerome Avouac1, Elide Toniolo2, Gemma Lepri3, Charlotte Hurabielle4, Anaïs Vallet5 and Yannick Allanore6, 1Rheumatology A department and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, 2Rheumatology Unit. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 3Department of Internal Medicine, Rheumatology Section, Transition Clinic, University of Florence, Italy, Florence, Italy, 4Rheumatology A department, paris Descartes University, Cochin Hospital, Paris, France, 5Rheumatology A department, Paris Descartes University, Cochin Hospital, Paris, France, 6Paris Descartes University, Rheumatology A department, Cochin Hospital, And Eular Scleroderma Trials And Research (EUSTAR) Board, Paris, France

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: nailfold capillaroscopy and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Nailfold videocapillaroscopy (NVC) is a simple, non-invasive and inexpensive imaging technique that allows a detailed assessment of skin microcirculation. Although NVC has face and content validity for the detection of microvascular damages related to systemic sclerosis (SSc), its sensitivity to change has not been assessed in detail. Our aim was to determine in a prospective cohort the merit of NVC to detect meaningful changes over time and whether these changes are associated with disease progression.

Methods: A prospective cohort of 140 SSc patients was recruited over a 12-month period and was followed up on an annual basis for 3 years. NVC was performed at inclusion and repeated once a year by four investigators (ET, GL, CH and AV) according to a standardized procedure. NVC pictures were analysed by one investigator (JA) and classified as early, active and late patterns. Organ progression was defined according to validated definitions. The worsening of the Medsger severity scale (from category 1-2 to category 3-4) was considered as a marker of disease progression. 

Results: The mean ± standard deviation (SD) age of the 140 patients (111 women) was 56±11 year old and the mean ± SD disease duration was 9±8 years at baseline. 55 patients had the diffuse cutaneous subset. At least 3 annual NVC evaluations were available for each patient. A change of NVC pattern was observed in 29 SSc patients (21%) during the follow-up period.

A progression from a normal or early NVC pattern to an active NVC pattern was detected in 15 patients (10%). Patients who progressed to the active NVC pattern were more likely to have shorter disease duration (6±7 years vs. 11±9 years, p=0.03). Progression was independent of age, gender, cutaneous subset, past or current digital ulcers (DU), and use of vasodilators at baseline. Patients who progressed to the active NVC pattern were significantly less at risk to develop ischemic DU during follow-up (hazard ratio, HR: 0.78, 95% Confidence Interval, CI 0.17-0.95).

A progression to a late NVC pattern was observed in 14 patients (10%). Patients with the diffuse cutaneous subset and with precapillary PAH at baseline were more likely to progress to a late NVC pattern (HR: 2.39, 95% CI 1.03-7.10 and HR: 13.30, 95% CI 2.46-71.99, respectively). Progression to the late pattern was independent of age, sex, disease duration, past or current DU, and use of vasodilators at baseline. Progression to a late NVC pattern was associated with the occurrence of new ischemic DU (HR: 4.51, 95% CI 1.68-12.14), lung vascular progression (HR: 5.12 95% CI 1.23-21.27), progression of skin fibrosis (HR: 3.70, 95% CI 1.14-11.94) and worsening of Medsger disease severity scale (HR: 4.47, 95% CI 1.63-12.26).

Conclusion: Change of the NVC pattern was observed in 20% of patient with SSc during a follow-up of 3 years. NVC has the ability to detect meaningful changes over time associated with markers of disease progression. Our results support the use of NVC for the routine follow-up of SSc patients in order to improve their risk stratification. NVC might be used in the future to select high-risk patients and change to a late NVC pattern might be regarded as potential surrogate marker for disease severity.


Disclosure: J. Avouac, None; E. Toniolo, None; G. Lepri, None; C. Hurabielle, None; A. Vallet, None; Y. Allanore, None.

To cite this abstract in AMA style:

Avouac J, Toniolo E, Lepri G, Hurabielle C, Vallet A, Allanore Y. Sensitivity to Change of Nailfold Videocapillaroscopy and Relationship with Disease Progression [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/sensitivity-to-change-of-nailfold-videocapillaroscopy-and-relationship-with-disease-progression/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sensitivity-to-change-of-nailfold-videocapillaroscopy-and-relationship-with-disease-progression/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology